President Donald Trump has nominated Dr. Heidi Overton, a physician and senior White House health adviser, to serve as the next commissioner of the Food and Drug Administration. Trump made the announcement Wednesday on his Truth Social platform, praising Overton as a "ROCKSTAR" in his administration and asserting that her leadership is needed to keep the United States at the forefront of scientific discovery and medical cures.
Overton, who has been a key figure in domestic health policy, would step into an agency that has been shaken by a wave of senior staff departures and is widely viewed by healthcare stakeholders as increasingly politicized. Her nomination comes roughly three months after the resignation of Dr. Marty Makary, Trump's first FDA pick, who left amid internal friction and external pressure.
Overton is a staunch ally of Health and Human Services Secretary Robert F. Kennedy Jr. and a vocal proponent of the "Make America Healthy Again" movement. Last week, she stood alongside Trump as he signed an executive order aimed at reducing and separating the childhood vaccine schedule. She has urged states to adopt the administration's "gold standard" recommendations, which have drawn sharp criticism from pediatricians, medical associations, and public health officials who warn that such changes could endanger children.
"We are going to be working directly with states so that we're not reliant on the court case to resolve," Overton said, referring to an ongoing legal challenge to the administration's earlier attempt to alter the vaccination schedule.
Before joining the White House, Overton served as vice chair and chief policy officer at the America First Policy Institute (AFPI), a conservative think tank founded by Agriculture Secretary Brooke Rollins. Her background includes writing for AFPI, where she denounced abortion as "corrosive" to women and called for tighter restrictions on the prescribing of abortion pills.
The FDA has long been regarded as a nonpartisan, science-driven agency, with commissioners typically drawn from medical or bureaucratic ranks. But under the current administration, the agency faces intense political pressure from the top—including from Trump himself—on issues ranging from e-cigarette approvals to vaccine policy. Kennedy has been pushing for unregulated access to experimental peptides, while anti-abortion lawmakers are demanding the agency restrict or ban mifepristone, a widely used abortion medication that has been on the market for decades with a strong safety record.
Overton's nomination coincides with the FDA's ongoing review of mifepristone. Republicans and anti-abortion groups are pressing the agency to reverse a Biden-era rule that permits the drug to be prescribed via telehealth and mailed to patients, and some are urging the FDA to declare the drug unsafe and remove it from the market entirely—despite its long history of safe use.
Industry analysts have reacted with alarm. Chris Meekins, a Raymond James analyst who served at HHS during the first Trump administration, wrote in a research note that Overton's selection "will likely lead to more chaos at the agency" and predicted that "industry will view this pick as extremely troublesome and FDA career staff will continue to flee the agency." Meekins noted that Overton has "seemingly no real experience running anything of consequence," and warned that any "strong team" willing to fill senior roles would likely "quickly regret it."
If confirmed, Overton would inherit an agency at a crossroads, facing both a credibility crisis and a leadership vacuum. Her nomination is likely to intensify the debate over the FDA's independence and its role in shaping public health policy under a politically assertive administration.
